MedTrace Logo

Virtual Reality Exposure for Public Speaking Anxiety

NCT06214039 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-05-24

No results posted yet for this study

Summary

This study aims to examine the efficacy of exposure using virtual reality (VR) for public speaking anxiety in young adults in two treatment arms: a one-session VR exposure therapy with a 4-week online transition intervention versus a three-session VR exposure therapy with a 4-week online transition intervention. Previous studies have demonstrated that one-session therapy (OST) is comparable to prolonged exposure-based therapies in terms of effectively reducing public speaking anxiety. Moreover, VR offers many benefits compared to in-person exposure, namely the ability to produce anxiety-evoking stimuli without having to leave the therapist's room. However, OST VR exposure has not been directly compared to prolonged VR exposure and not for public speaking anxiety.

Conditions

  • Public Speaking Anxiety

Interventions

BEHAVIORAL

Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety

A 3-hour one session exposure therapy for public speaking anxiety

Sponsors & Collaborators

  • Linkoeping University

    collaborator OTHER_GOV

  • Stockholm University

    collaborator OTHER

  • Thomas More University of Applied Sciences

    collaborator OTHER

  • Vilnius University

    lead OTHER

Principal Investigators

  • Jonas Eimontas, PhD · Vilnius University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-14
Primary Completion
2025-05-31
Completion
2026-05-31

Countries

  • Lithuania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06214039 on ClinicalTrials.gov